Keywords
Skin
Vaccine
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify the mechanisms and evaluate the clinical impacts of the mRNA-4157 vaccine in combating melanoma recurrence, exploring the therapeutic possibilities of this novel approach. Literature review: Melanoma is one of the most aggressive and lethal skin cancers, characterized by a high metastatic rate and a poor prognosis in advanced stages. Despite the effectiveness of treatments such as surgical excision and immunotherapy in early stages, options for metastatic melanoma remain limited. In recent years, therapeutic vaccines have gained prominence for their safety and multi-target potential. The mRNA-4157 vaccine uses tumor antigens to induce a specific and efficient immune response, standing out as an innovative and cost-effective approach. Studies highlight the growing relevance of this strategy in light of the high incidence and mortality of melanoma, which has increased significantly over the past decades. Final considerations: The mRNA-4157 vaccine emerges as a promising ally in melanoma treatment, offering significant advancements in efficacy and safety. However, further studies are necessary to consolidate its application in different clinical contexts, particularly in cases of metastatic melanoma. Given the increasing prevalence of the disease, the development of more effective therapies is essential to improve clinical outcomes and reduce associated mortality.
References
ADAMIK J, et al. Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients. Nature communications, 2023; 14(1): 7211.
ASCIERTO PA, et al. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). Journal of translational medicine, 2022; 20(1): 391.
BAFALOUKOS D, et al. Evolution and progress of mRNA vaccines in the treatment of melanoma: Future prospects. Vaccines, 2023; 11: 3.
BHAVE P, et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British journal of cancer, 2021; 124(3): 574–580.
BIDRAM M, et al. mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. MDPI, 2021.
BIRA-KOVÁCS B, et al. Peptide vaccines in melanoma: Chemical approaches towards improved immunotherapeutic efficacy. Pharmaceutics, 2023; 15(2): 452.
BRIDAM M, et al. MRNA-based cancer vaccines: A therapeutic strategy for the treatment of melanoma patients. Vaccines, 2021; 9(10): 1060.
BURRIS HA, et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2019; 37(15): 2523–2523.
DEDEILIA A, et al Factors affecting recurrence and survival for patients with high-risk stage II melanoma. Annals of surgical oncology, 2024; 31(4): 2713–2726.
FRANZIN R, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: Where do we stand? Frontiers in immunology, 2020; 11: 574271.
GAINIR JF, et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discovery, 2024; 14:2209-2223.
HUPPERT LA e DAUD AI. Intratumoral therapies and in-situ vaccination for melanoma. Human vaccines & immunotherapeutics, 2022; 18(3): 1890512.
KEUNG EZ e GERSHENWALD JE. Clinicopathological features, staging, and current approaches to treatment in high-risk resectable melanoma. Journal of the National Cancer Institute, 2020; 112 (9): 875–885.
KIM HJ e KIM YH. Molecular frontiers in melanoma: Pathogenesis, diagnosis, and therapeutic advances. International journal of molecular sciences, 2024; 25(5): 2984.
LIU H, et al. Immunotherapy and delivery systems for melanoma. Human vaccines & immunotherapeutics, 2024; 20(1): 2394252.
LOPES L, et al. The influence of checkpoint inhibitors on cancer patient survival. Brazilian Journal of Health Review, 2022; 5(2): 5635-5646.
OTT PA, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017, 547(7662): 217–221.
PATTON EE, et al. Melanoma models for the next generation of therapies. Cancer cell, 2021; 39(5): 610–631.
PING H, et al. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine. Investigational new drugs, 2022; 40(6): 1173–1184.
QUINTANILHA T e BECKER R. Vacinas de mRNA: Uma nova era na produção de imunizantes. Revista Perspectiva: Ciência e Saúde, 2024; 8(1).
REZAEI T, et al. Strategies in DNA vaccine for melanoma cancer. Pigment cell & melanoma research, 2021; 34(5): 869–891.
WEBER JS, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet, 2024; 403(10427): 632-644.
XIE N, et al. Neoantigens: promising targets for cancer therapy. Signal transduction and targeted therapy, 2023; 8(1): 9.
XU Z e FISHER DE. mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic. Frontiers in Immunology, 2023; 14: 1155728.